GLP1R and inflammatory bowel disease: Overall, reductions ranged from approximately -16 lbs (SD = 13) to -26 lbs (SD = 20), with longer follow-up studies (up to 450 days) showing median reductions of -8.15 kg (range: -15.9 to -2.2 kg).<h4>Conclusions</h4>GLP-1 RAs are effective pharmacological adjuncts for weight loss in patients with obesity and IBD, with outcomes modulated by treatment duration and agent selection.